Musings from The Power List: Miguel Forte
By Miguel Forte
September 8, 2026
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
4 min read
False
Advertisement
Cell & Gene
CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
September 8, 2026
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
2 min read
Manufacturing Reality Behind Personalized Cancer Vaccines
By Amy Walker
September 7, 2026
As personalized cancer vaccines move closer to commercialization, manufacturers must rethink DNA production to deliver batch-for-one treatments with the required speed, consistency, and quality
3 min read
CAR T Before Surgery Improves Glioblastoma Control in Mice
September 7, 2026
Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival
2 min read
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
August 31, 2026
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
4 min read
This Week’s CGT News: Antifreeze Sugars Protect CAR T Cells
August 24, 2026
A new preservation method could remove a major barrier to treatment, the FDA approves the first gene therapy for GSDIa, and ultrasound directs CAR T cells toward solid tumors
5 min read
The Biggest Bottlenecks Holding Back Cell and Gene Therapy
August 24, 2026
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
9 min read
The Road to Commercial-Scale iPSC Cell Therapy
August 19, 2026
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
5 min read
This Week’s CGT News: T-Cell Therapy Clears Pediatric Solid Tumor
August 17, 2026
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
3 min read
Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
